Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies for Major Depressive Disorders (MDD)
Shots:
- The P-III RAP-MD (01-02-03-04) studies involve assessing of Rapastinel (450mg- 225mg) vs PBO as an adjunctive treatment of MDD
- The P-III RAP-MD-04 study demonstrated unmet 1EPs & 2EPs. RAP-MD (01-02-03) studies resulted that Rapastinel was well tolerated with no psychotomimetic side effects
- Rapastinel (IV- qw) is a novel anti-depressant- enhanced NMDAR activity by acting as a partial agonist at the glycine site
Ref: Allergen | Image: Endpoints News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
